# US 2016/0256525 A1 · Muteins of tear lipocalin and methods for obtaining the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256525 A1
- Document ID: US20160256525A1
- Status: Published application
- Kind: A1
- Application number: 14/981,589
- Filed: 2015-12-28
- Published: 2016-09-08
- Earliest claimed: 2006-08-01
- Assignees: Pieris AG
- Applicants: Pieris AG
- Inventors: Kristian Jensen; Martin Huelsmeyer; Steffen Schlehuber; Andreas Hohlbaum; Arne Skerra; Eric Boudreau; Richard Jones; Ian Kimber; Rebecca Dearman
- Web page: https://patentgrep.com/patent/US20160256525A1

## CPC

- A61K 38/1709: {from mammals}
- A61K 38/38: Albumins
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/06: Antiasthmatics
- A61P 27/00: Drugs for disorders of the senses
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/435: from animals; from humans
- C07K 14/47: from mammals
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 2333/70521: CD28, CD152
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.

## Claims

### Claim 1

A method of binding a non-natural ligand of human tear lipocalin in a subject in need thereof, comprising administering to the subject a mutein of human tear lipocalin or a pharmaceutical composition comprising such mutein, wherein at least one of the cysteine residues occurring at sequence positions 61 and 153 of the linear wild type amino acid sequence of mature human tear lipocalin (SEQ ID NO: 71) is replaced by other amino acids and wherein at least 12 mutated amino acid residues are present at any of the sequence positions 26-34, 56-58, 80, 83, 104-106, and 108 of the linear wild type amino acid sequence of mature human tear lipocalin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the non-natural ligand is selected from the group consisting of a peptide, a protein, a fragment or a domain of a protein, and a small organic molecule or wherein said peptide includes an amyloid beta peptide and said protein includes fibronectin or a domain thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the non-natural ligand is selected from the group consisting of interleukin 4 receptor alpha chain (IL-4 receptor alpha), vascular endothelial growth factor receptor 2 (VEGF-R2) and vascular endothelial growth factor (VEGF).

### Claim 4 (depends on 1)

The method of claim 1, wherein the mutein is conjugated to or at its N-terminus or its C-terminus operably fused to a member selected from the group consisting of an enzyme, a toxin, a protein or a protein domain, a peptide, a signal sequence and an affinity tag.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mutein is employed in conjugated form or as a fusion protein.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mutein is conjugated to or at its N-terminus or its C-terminus operably fused to an antibody or a mutein of human lipocalin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the mutein is fused to a moiety that extends the serum half-life of the mutein.

### Claim 8 (depends on 7)

The method of claim 7, wherein the moiety that extends the serum half-life is selected from the group consisting of an Fc part of an immunoglobulin, a CH3 domain of an immunoglobulin, a CH4 domain of an immunoglobulin, albumin or an albumin fragment, an albumin binding peptide, an albumin binding protein and transferrin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the mutein is conjugated to a label selected from the groups consisting of organic molecules, enzyme labels, radioactive labels, fluorescent labels, chromogenic labels, luminescent labels, haptens, digoxigenin, biotin, metal complexes, metals, colloidal gold and a moiety that extends the serum half-life of the mutein.

### Claim 10 (depends on 1)

The method of claim 1, wherein the mutein has an amino acid sequence as set forth in any one of SEQ ID NOs: 2-8, 26-33 and 44-47.
